Mounjaro weight loss in London: what the clinical evidence actually shows

What SURMOUNT-1 actually found, and why it matters for Londoners weighing their options

The SURMOUNT-1 trial is the cornerstone of what we know about tirzepatide for weight management. Published in the New England Journal of Medicine, it followed 2,539 adults with obesity over 72 weeks. Participants on 15 mg tirzepatide lost an average of roughly 20–21% of their body weight. Those on 10 mg averaged around 19%. These figures come from a setting with structured lifestyle support alongside the medicine, they are not a standalone pill result.

That distinction matters. The licence covers Mounjaro as an adjunct to a reduced-calorie diet and increased physical activity, not a replacement for them. In practice, many people find appetite suppresses noticeably within the first few weeks, which makes the dietary side easier to sustain than it sounds on paper. Our clinical team discusses realistic expectations at the consultation stage, before any prescription is written.

For context on how tirzepatide compares to semaglutide, the SURMOUNT-5 head-to-head trial (published in the New England Journal of Medicine in 2025) found tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks. Which is appropriate for a given person is a clinical judgement, not a league-table decision.

Who the licence covers, and where London's NHS criteria sit right now

Privately, Mounjaro is licensed for adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as hypertension, type 2 diabetes, high cholesterol or obstructive sleep apnoea. BMI figures are a starting point; the prescriber looks at the whole picture. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance.

On the NHS in England, access to tirzepatide is rolling out in phases. NICE's appraisal TA1026 recommends it for adults with a BMI of 35 or above plus at least one weight-related comorbidity, with GP practices able to prescribe under the 2026/27 contract from April 2026. Cohort 2 (covering BMI 35–39.9 with four or more qualifying conditions) activated in June 2026. Waiting lists in London vary considerably by borough and GP practice participation.

Private treatment through a regulated online pharmacy sidesteps those waiting lists entirely, subject to clinical suitability. If you are curious about what the private route involves day-to-day, the guide to Mounjaro access in London covers the practical steps in detail.

Side effects and what to watch for during treatment in London

The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and burping appear most often in the first weeks after starting or after a dose increase, then settle for most people. Fatigue, headache and dizziness are also reported.

Two things to take seriously: first, severe and persistent stomach pain that spreads towards the back, with or without vomiting, should prompt urgent medical attention, the MHRA issued a Drug Safety Update in January 2026 reinforcing that acute pancreatitis is a known, if infrequent, risk with GLP-1 medicines. Second, anyone taking an oral contraceptive pill should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide can slow gastric absorption; this applies to the pill specifically, not to patches or other non-oral methods.

Side effects are manageable for most people, but they are real. Rushing through the dose schedule to get faster results is the wrong move; titration exists for a reason. If you want to understand how Mounjaro weight loss tends to progress across the first eight weeks, that page sets out what most people experience as they move through the early stages of treatment. You can also read more about what weight loss on Mounjaro typically looks like across the full course of treatment.

Getting started: how the private route works and what the cost picture looks like

There is no GP referral required to access Mounjaro privately. The process at a regulated online pharmacy is: complete a clinical consultation, have it reviewed by a GPhC-registered prescriber (a real clinician, reading your answers personally), and, if approved, receive your treatment. At nume, orders placed by 12 pm Monday to Friday go out the same day and arrive the next working day with DPD in plain packaging, useful to know if you are planning around a bank holiday or ordering on a Friday before a long weekend.

On cost: since Eli Lilly revised UK list prices in September 2025, private Mounjaro prices have typically ranged from roughly £149 to £375 per month depending on dose and provider, as widely reported at the time. The honest framing here is that price alone is a poor guide to quality of care. What you want to know is whether the pharmacy appears on the GPhC register, whether a named prescriber reviews your case, and whether there is genuine clinical support if something goes wrong. You can verify any online pharmacy at the GPhC pharmacy register directly.

For a fuller picture of what different services include (and what headline prices sometimes leave out) the cost context page sets it out plainly. If you are ready to explore whether Mounjaro could be appropriate for you, the free consultation is the right starting point, and our overview of Mounjaro as a weight loss jab covers how it works, what to expect and how it compares to other injectable options. You can also find detail on how Mounjaro affects weight over time, including what the evidence says about maintaining results after treatment.